<DOC>
	<DOC>NCT00648323</DOC>
	<brief_summary>The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.</brief_summary>
	<brief_title>Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<criteria>Taiwanese male subjects between 50 and 80 years of age who had: a primary diagnosis of BPH, defined as having an enlarged prostate (confirmed by digital rectal examination [DRE] and/or Bmode ultrasound); an IPSS score of ≥12; and a Qmax in the range of 5 to 15 mL/sec in a total voided volume of ≥150 mL, were eligible for the study. Exclusion criteria include but not limited to: Previous prostate surgery, presence of a prostate stent or microwave thermotherapy and/or balloon dilatation within the previous 6 months Concomitant therapy or previous therapy within 14 days with agents known to affect bladder or urethral function.</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Benign Prostate Hyperplasia</keyword>
</DOC>